A previous suggestion that antiepileptic drugs may induce color vision
deficiencies prompted us to examine whether color vision deficiencies
may occur at lower drug serum concentrations than those associated wi
th symptoms of neurotoxicity. Eighty patients presenting with epilepsy
received monotherapies of valproic acid, phenytoin, or carbamazepine;
18 patients did not receive antiepileptic drug therapy. Color vision
was tested by the Farnsworth-Munsell 100-hue test, spectral sensitivit
y, and the newly developed tritan screening plates. Patients treated w
ith phenytoin or carbamazepine developed blue-yellow color vision defi
ciencies. In contrast, patients exposed to valproic acid or receiving
no drug treatment showed normal color vision. There was a significant
correlation (p < 0.0001) between signs of neurotoxicity induced by phe
nytoin or carbamazepine and blue-yellow color vision deficiencies. In
contrast, we found no correlation between these signs of neurotoxicity
and the drug serum concentrations (p = 0.0637). Color vision testing
in epileptic patients treated with phenytoin or carbamazepine appears
to be a sensitive method for early detection and monitoring of clinica
l neurotoxicity.